Anne Wojcicki regains control of 23andMe, the company she co-founded and led as CEO, through her nonprofit TTAM with a $305 million bid at a bankruptcy auction.

Regeneron Pharmaceuticals has declined to submit a new bid for genetic testing company 23andMe exceeding its original winning bid of $256 million, a company spokesperson told Reuters on Monday.

Former 23andMe CEO Anne Wojcicki outbids Regeneron with a $305 million offer through her nonprofit TTAM to regain control of the DNA-testing company she co-founded.

In a surprise twist, 23andMe founder and former CEO Anne Wojcicki is set to regain control of the DNA company's assets, according to a press release from 23andMe. In May, a company called ...

Anne Wojcicki is set to regain control of 23andMe after a $305 million bid from a nonprofit she controls topped Regeneron Pharmaceuticals' offer for the DNA-testing company in a bankruptcy auction.

Anne Wojcicki, the co-founder and former CEO of 23andMe, is poised to regain control of the DNA-testing company after a nonprofit she controls topped a prior bid. 23andMe said Friday that a ...

23andMe CEO Anne Wojcicki has been trying to take the DNA testing company private this past year, making clear along the way that she would oppose any deal to sell the business to someone else.

Former 23andMe CEO Anne Wojcicki now runs TTAM Research Institute, which outbid Regeneron in an auction for the bankrupt company’s assets.

In a surprise twist, 23andMe founder and former CEO Anne Wojcicki is set to regain control of the DNA company's assets, according to a press release from 23andMe.